1
|
Yang X, Chang R, Dettling T, Desai R, Gao C, Banatwala A, Ng S, Ahsan S, Duh MS. HSR24-150: Real-World Treatment Patterns of Selumetinib Among Patients With Neurofibromatosis Type I and Plexiform Neurofibroma in the United States. J Natl Compr Canc Netw 2024; 22:HSR24-150. [PMID: 38579758 DOI: 10.6004/jnccn.2023.7212] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/07/2024]
Affiliation(s)
| | | | | | | | - Chi Gao
- 2Analysis Group, Inc., Boston, MA
| | | | - Sydney Ng
- 4Analysis Group, Inc., Los Angeles, CA
| | | | | |
Collapse
|
2
|
Sanchez L, Chari A, Cheng M, Cherepanov D, DerSarkissian M, Huang F, Stull DM, Dabora J, Young M, Noga SJ, Pi S, Zhang M, Banatwala A, Duh MS, Ailawadhi S. Comparison of health care costs and resource utilization for commonly used proteasome inhibitor-immunomodulatory drug-based triplet regimens for the management of patients with relapsed/refractory multiple myeloma in the United States. J Manag Care Spec Pharm 2023; 29:1205-1218. [PMID: 37776124 PMCID: PMC10776283 DOI: 10.18553/jmcp.2023.23031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/01/2023]
Abstract
BACKGROUND: Economic differences among currently available proteasome inhibitors (PI)-based lenalidomide-dexamethasone (Rd)-backbone triplet regimens-ixazomib (I), bortezomib (V), and carfilzomib (K) plus Rd-remain poorly understood. OBJECTIVE: To assess health care resource utilization (HCRU) and health care costs of patients with relapsed/refractory multiple myeloma (RRMM) in the United States treated with IRd, VRd, and KRd. METHODS: This retrospective longitudinal cohort study using IQVIA PharMetrics Plus adjudicated claims US data (January 1, 2015, to September 30, 2020) included adult patients with all available data who initiated IRd, VRd, or KRd in second line of therapy or later (LOT2+) on or after September 1, 2015. The index date was the treatment initiation date for each LOT (multiple LOTs per patient were included) and the baseline was 6 months pre-index. MM-related and all-cause HCRU/costs were assessed during follow-up and reported per patient per month (PPPM; 2020 US Dollars). For MM-related costs only, treatment administration costs were excluded from outpatient (OP) costs and instead summed with pharmacy costs. HCRU/costs were compared between treatment groups using generalized linear models (GLMs). Cost variables were compared using 2-part models and GLM with log transformation and γ distribution. Inverse probability of treatment weighting (IPTW) adjusted for imbalance of baseline confounders across treatment groups. RESULTS: The study included 511 patients contributing 542 LOTs (IRd: n = 153; VRd: n = 262; KRd: n = 127). Before IPTW, mean observed time spent on therapy was 8.5, 9.3, and 7.3 months for the IRd, VRd, and KRd cohorts, respectively. During follow-up and after IPTW, IRd and VRd were associated with significantly fewer OP visits vs KRd. Post-IPTW comparisons of MM-related costs for IRd vs KRd yielded lower OP costs for IRd (mean diff. PPPM: -$3,428; P < 0.001), contributing to lower total medical costs (-$3,813; P < 0.001) and total health care cost savings with IRd vs KRd (-$5,813; P = 0.001). MM-related OP costs were lower for VRd (mean diff. PPPM: -$3,543; P < 0.001) than KRd, reducing its total MM-related medical costs (-$3,997; P = 0.002), leading to total MM-related health care cost savings with VRd vs KRd (-$12,357; P < 0.001). All-cause cost comparisons yielded similar results (total health care cost savings for IRd and VRd vs KRd: -$6,371 and -$13,629, respectively; all P < 0.001). CONCLUSIONS: From the US insurance-payer perspective, patients treated with IRd and VRd had significant medical cost savings vs KRd due to lower OP costs when excluding treatment administration costs. The differential economic impacts of PI-Rd regimens in this study may help to inform treatment decisions for patients with MM. DISCLOSURES: This study and article were supported by Takeda Development Center Americas, Inc. Dr Sanchez has no conflicts to declare. Dr Chari has the following relationships: Research Support/Principal Investigator: Amgen, Array Biopharma, Celgene, Glaxo Smith Klein, Janssen, Millenium/Takeda, Novartis Pharmaceuticals, Oncoceutics, Pharmacyclics, Seattle Genetics; Consultant: Amgen, Bristol-Myers Squibb, Celgene, Millenium/Takeda, Janssen, Karyopharm; Scientific Advisory Board: Amgen, Celgene, Millenium/Takeda, Janssen, Karyopharm, Sanofi, Seattle Genetics. Drs Cherepanov, Huang, Dabora, and Noga are current employees of Takeda, while Drs Stull and Young are ex-employees of Takeda; Drs Cherepanov and Huang also own stocks in Takeda. Dr DerSarkissian, Ms Cheng, Ms Zhang, Mr Banatwala, and Dr Duh are employees of Analysis Group, Inc. (AG), a consulting firm that received funding from Takeda to conduct this study. Ms Pi was an employee of AG at the time of the study. Dr Ailawadhi has the following relationships to declare: Research Support and Consulting for BMS, GSK, and Janssen; Research Support from AbbVie, Arch Oncology, Cellectar, Medimmune, Pharmacyclics, and Xencor; Consulting for Beigene, Oncopeptides, Regeneron, Sanofi, and Takeda.
Collapse
Affiliation(s)
| | - Ajai Chari
- Icahn School of Medicine at Mount Sinai, New York, NY
| | - Mu Cheng
- Analysis Group, Inc., Boston, MA
| | | | | | - Fei Huang
- Takeda Development Center Americas, Lexington, MA
| | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Singer D, Thompson-Leduc P, Gupta D, Poston S, Cheng WY, Ma S, Pawlowski JE, Duh MS, Devine F, Banatwala A, Bernstein E, Farraye FA. Economic and Clinical Burden of Herpes Zoster Among Patients With Inflammatory Bowel Disease in the United States. Crohns Colitis 360 2023; 5:otad033. [PMID: 37497018 PMCID: PMC10368335 DOI: 10.1093/crocol/otad033] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Indexed: 07/28/2023] Open
Abstract
Background Patients with ulcerative colitis (UC) or Crohn's disease (CD) are at increased risk of herpes zoster (HZ); however, relevant cost and healthcare resource utilization (HCRU) data are limited. Methods We estimated HCRU (hospitalization, emergency department [ED], and outpatient visits) and costs in patients with UC or CD, with and without HZ, using administrative claims data (October 2015-February 2020). HCRU and costs (2020 US dollars) were compared at 1 month, 1 quarter, and 1 year after the index date, using propensity score adjustment and generalized linear models. Results In total, 20 948 patients were included: UC+/HZ+ (n = 431), UC+/HZ- (n = 10 285), CD+/HZ+ (n = 435), and CD+/HZ- (n = 9797). Patients with HZ had higher all-cause HCRU rates and all-cause total healthcare costs relative to those without HZ. In the first month, adjusted incidence rate ratios (aIRRs) for hospitalizations and ED visits for patients with UC and HZ compared with UC alone were 2.87 (95% confidence interval [CI], 1.93-4.27) and 2.66 (95% CI,1.74-4.05), respectively; for those with CD and HZ, aIRRs were 3.34 (95% CI, 2.38-4.70) and 3.31 (95% CI, 2.32-4.71), respectively, compared with CD alone (all P < .001). Adjusted cost differences in UC and CD cohorts with HZ over the first month were $2189 and $3774, respectively, chiefly driven by higher inpatient costs. The incremental impact on HCRU and costs in cohorts with HZ predominantly occurred during the first quarter following diagnosis. Conclusions HZ is associated with increased HCRU and costs in patients with UC and CD, especially shortly after diagnosis.
Collapse
Affiliation(s)
- David Singer
- Address correspondence to: David Singer, PharmD, MS, GSK, US Health Outcomes and Epidemiology—Vaccines, FMC Tower Suite 1700, 2929 Walnut Street, Philadelphia, PA 19104, USA. Phone: +16465995595 ()
| | - Philippe Thompson-Leduc
- Analysis Group, Inc., Health Economics and Outcomes Research, 1190 Avenue des Canadiens-de-Montréal, Suite 1500, Montréal, QC H3B 0G7, Canada
| | - Deepshekhar Gupta
- Analysis Group, Inc., Health Economics and Outcomes Research, 1010 El Camino Real, Suite 310, Menlo Park, CA 94025, USA
| | - Sara Poston
- GSK, US Health Outcomes and Epidemiology—Vaccines, FMC Tower Suite 1700, 2929 Walnut Street, Philadelphia, PA 19104, USA
| | - Wendy Y Cheng
- Analysis Group, Inc., Health Economics and Outcomes Research, 111 Huntington Avenue, 14 Floor, Boston, MA 02199, USA
| | - Siyu Ma
- GSK, US Health Outcomes and Epidemiology—Vaccines, FMC Tower Suite 1700, 2929 Walnut Street, Philadelphia, PA 19104, USA
- Tufts Medical Center, 800 Washington Street, Boston, MA 02111, USA
| | - John E Pawlowski
- GSK, Medical Affairs, FMC Tower Suite 1700, 2929 Walnut Street, Philadelphia, PA 19104, USA
| | - Mei Sheng Duh
- Analysis Group, Inc., Health Economics and Outcomes Research, 111 Huntington Avenue, 14 Floor, Boston, MA 02199, USA
| | - Francesca Devine
- Analysis Group, Inc., Health Economics and Outcomes Research, 151 West 42 Street, 23rd Floor, New York, NY 10036, USA
| | - Azeem Banatwala
- Analysis Group, Inc., Health Economics and Outcomes Research, 333 South Hope Street, 27 Floor, Los Angeles, CA 90071, USA
| | - Emma Bernstein
- Analysis Group, Inc., Health Economics and Outcomes Research, 111 Huntington Avenue, 14 Floor, Boston, MA 02199, USA
- Baylor University, Department of Political Science, One Bear Place #97276, Waco, TX 76798-7276, USA
| | - Francis A Farraye
- Mayo Clinic, Division of Gastroenterology and Hepatology, 4500 San Pablo Road, Jacksonville, FL 32224, USA
| |
Collapse
|